Karim Kader, MD, PhD, explains how controversies have led to the decline of PSA screening, and therefore fewer diagnoses and the presentation of more high-grade disease. He suggests that the use of a prostate genetic score, based on SNPs, can more efficiently guide patient selection.
Read More
E. David Crawford, MD, discusses the wide range of clinical possibilities related to prostate cancer imaging with a novel 29 MHz micro-ultrasound technology. He specifically deliberates the possibility of micro-ultrasound to improve screening pathways and focal therapy protocols.
Read More
J. Kellogg Parsons, MD, MHS, FACS, discusses rising concerns of sepsis following transrectal ultrasound (TRUS) prostate biopsy. He then reviews the literature proving a reduction of infection-based complications with transperineal biopsy and argues for the transperineal approach superseding TRUS in clinical practice.
Read More
J. Kellogg Parsons, MD, MHS, FACS, discusses the role of the National Comprehensive Cancer Network (NCCN) Prostate Cancer Early Detection guidelines in the PSA screening debate. He then provides commentary on the three algorithms included in the guidelines.
Read More
J. Kellogg Parsons, MD, MHS, FACS, reviews general principles of patient safety as applied to urologic practice. He provides practical instructions about handling urologic complications, specifically rhabdomyolysis, venous thromboembolism (VTE), air embolism, laparoscopic bowel injury, and prostate biopsy infections.
Read More